PERRIGO Co plc (PRGO) Stock Analysis and Metrics

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic CIK: 0001585364

Market Cap 1.50 Bn

P/E -0.84

P/S 0.36

Div. Yield 0.11

ROIC (Qtr) -0.01

Total Debt (Qtr) 3.63 Bn

Revenue Growth (1y) (Qtr) -7.16

Add ratio to table...

About

Perrigo Company plc is a leading pure play self care company that develops, manufactures and markets high quality health and wellness solutions. The company operates primarily in the over the counter (OTC) self care sector, offering products across categories such as upper respiratory, nutrition, digestive health, pain and sleep aids, oral care, healthy lifestyle, skin care, women's health, vitamins, minerals, and supplements. Perrigo serves consumers mainly in North America and Europe through a mix of store brand and branded offerings. Perrigo...

Perrigo Company plc is a leading pure play self care company that develops, manufactures and markets high quality health and wellness solutions. The company operates primarily in the over the counter (OTC) self care sector, offering products across categories such as upper respiratory, nutrition, digestive health, pain and sleep aids, oral care, healthy lifestyle, skin care, women's health, vitamins, minerals, and supplements. Perrigo serves consumers mainly in North America and Europe through a mix of store brand and branded offerings.

Perrigo generates revenue by selling store brand products sold under retailers’ private labels and its own branded self care goods to a broad range of customers. Its sales flow through major retail drug, supermarket, and mass merchandise chains, e commerce retailers, wholesalers, and pharmacy chains in Europe. No single product accounts for more than 5% of total revenue, while Walmart contributed 12.9% of consolidated net sales in 2025.

Perrigo holds a leading position as the top store brand private label provider in North America and maintains a strong branded portfolio in Europe. Its competitors include manufacturers such as Dr. Reddy’s Laboratories, LNK International, PL Developments, Aurobindo Pharma, and Sun Pharmaceutical Industries, as well as large consumer health firms like Haleon, Kenvue, Procter & Gamble, Reckitt Benckiser, Abbott Nutrition, Bayer AG, Opella, Philips, Teva, Viatris, and Stada. The company’s competitive advantages stem from a diverse product portfolio, strong research and development capabilities, deep consumer insights, extensive global commercial infrastructure, and a supply chain that leverages scale across multiple dosage forms and geographies.

Perrigo’s customer base comprises major global, national, and regional retail drug stores, supermarkets, and mass merchandise chains, e commerce retailers, wholesalers, and pharmacy networks in Europe. Walmart Inc. is the largest individual customer, representing 12.9% of 2025 consolidated net sales, while the top ten customers together accounted for 47% of total revenue that year.

Investment thesis

Bull case

Perrigo’s store‑brand over‑the‑counter portfolio has demonstrated resilient share‑gain momentum, even amid a broader consumer health softness that has weighed on peers. Over the last thirteen weeks the company has added 90 basis points of volume share in the U.S. across key categories such as smoking cessation, allergy, and women’s health, a trend that is rarely achieved by incumbent players in a highly competitive environment. Management’s narrative underscores that this growth is largely driven by disciplined execution, a robust multi‑price point strategy, and targeted A&P investments that have delivered incremental sales of approximately $30 million beyond forecasts. The fact that the company is able to capture additional share while its overall top line has slipped suggests a durable underlying demand that can be leveraged when market conditions normalize. {bullet} The company’s strategic 3S plan – stabilize, streamline, strengthen – has yielded tangible cost efficiencies that are likely to improve the margin profile over the next 12 months. Project Energize has already delivered $163 million in gross annual savings, comfortably exceeding the midpoint of the $140 million to $170 million target range, and the supply‑chain reinvention program is on track to generate an additional $150 million to $200 million in benefits by year‑end. These initiatives not only offset any compression from softer consumption but also create a margin cushion that can be re‑allocated to higher‑yielding initiatives such as brand building, digital expansion, and accelerated innovation pipelines. {bullet} Perrigo’s divestiture of the dermocosmetics business, scheduled for completion in 2026, will free up significant capital and further reduce leverage, enabling the firm to reinvest in core high‑margin OTC segments. The proceeds are earmarked for debt reduction, which will tighten the net debt to adjusted EBITDA ratio from the current 3.8x toward the company’s prior 3.5x target, thereby enhancing financial flexibility and supporting dividend stability. This deleveraging, coupled with the cash‑flow generation from the existing OTC business, positions Perrigo to fund new product launches and scale successful brands into new geographies with minimal financing costs. {bullet} While infant formula represents a smaller slice of Perrigo’s overall revenue (~10% of 2024 net sales), its strategic review could unlock hidden value. If the company decides to sell or spin off the unit, the transaction could unlock a valuation premium that reflects the lower risk profile of the remaining OTC portfolio and the potential for higher return on capital. The current $240 million investment that was paused can be reassessed against a clearer cost structure; if the unit is deemed non‑strategic, the company could avoid the opportunity cost of capital tied up in an underperforming segment, thereby freeing resources for higher‑growth initiatives. {bullet} Tariff exposure, which management estimates at $40–$50 million, is being mitigated through pricing adjustments and supply‑chain sourcing changes that the company claims are already underway. Even if the full impact is realized in the near term, the company’s operating margin is projected to hold near 15% in 2025, suggesting that the margin compression from tariffs will be absorbed without materially eroding profitability. Moreover, the firm’s diversified geographic footprint means that any adverse tariff adjustments in one region can be offset by stable performance elsewhere, reducing the overall risk to earnings. {bullet} The company’s investment in innovation, especially its focus on small‑price‑point molecules and the accelerated roll‑out of new products, indicates a pipeline that could capture additional share in categories where consumers are price‑sensitive. The management team’s emphasis on “highly focused innovation processes” signals a commitment to developing differentiated products that can command premium pricing within the store‑brand space, which historically yields better margins than national brands. If the company can successfully translate these pipeline initiatives into commercial success, the upside potential to organic net sales growth could be significant, especially as the broader OTC market begins to recover. {bullet} Finally, the market’s current focus on the negative aspects of the infant formula review may lead to an over‑discount of Perrigo’s OTC prospects. The narrative of a struggling infant formula unit, combined with a lowered 2025 EPS outlook, may eclipse the company’s solid share‑gain trajectory in the OTC arena. A rational reassessment of the company’s value, recognizing the momentum in OTC and the potential de‑leveraging benefits, could result in a more favorable valuation multiple that reflects the firm’s true growth trajectory.

Perrigo’s store‑brand over‑the‑counter portfolio has demonstrated resilient share‑gain momentum, even amid a broader consumer health softness that has weighed on peers. Over the last thirteen weeks the company has added 90 basis points of volume share in the U.S. across key categories such as smoking cessation, allergy, and women’s health, a trend that is rarely achieved by incumbent players in a highly competitive environment. Management’s narrative underscores that this growth is largely driven by disciplined execution, a robust multi‑price point strategy, and targeted A&P investments that have delivered incremental sales of approximately $30 million beyond forecasts. The fact that the company is able to capture additional share while its overall top line has slipped suggests a durable underlying demand that can be leveraged when market conditions normalize. {bullet} The company’s strategic 3S plan – stabilize, streamline, strengthen – has yielded tangible cost efficiencies that are likely to improve the margin profile over the next 12 months. Project Energize has already delivered $163 million in gross annual savings, comfortably exceeding the midpoint of the $140 million to $170 million target range, and the supply‑chain reinvention program is on track to generate an additional $150 million to $200 million in benefits by year‑end. These initiatives not only offset any compression from softer consumption but also create a margin cushion that can be re‑allocated to higher‑yielding initiatives such as brand building, digital expansion, and accelerated innovation pipelines. {bullet} Perrigo’s divestiture of the dermocosmetics business, scheduled for completion in 2026, will free up significant capital and further reduce leverage, enabling the firm to reinvest in core high‑margin OTC segments. The proceeds are earmarked for debt reduction, which will tighten the net debt to adjusted EBITDA ratio from the current 3.8x toward the company’s prior 3.5x target, thereby enhancing financial flexibility and supporting dividend stability. This deleveraging, coupled with the cash‑flow generation from the existing OTC business, positions Perrigo to fund new product launches and scale successful brands into new geographies with minimal financing costs. {bullet} While infant formula represents a smaller slice of Perrigo’s overall revenue (~10% of 2024 net sales), its strategic review could unlock hidden value. If the company decides to sell or spin off the unit, the transaction could unlock a valuation premium that reflects the lower risk profile of the remaining OTC portfolio and the potential for higher return on capital. The current $240 million investment that was paused can be reassessed against a clearer cost structure; if the unit is deemed non‑strategic, the company could avoid the opportunity cost of capital tied up in an underperforming segment, thereby freeing resources for higher‑growth initiatives. {bullet} Tariff exposure, which management estimates at $40–$50 million, is being mitigated through pricing adjustments and supply‑chain sourcing changes that the company claims are already underway. Even if the full impact is realized in the near term, the company’s operating margin is projected to hold near 15% in 2025, suggesting that the margin compression from tariffs will be absorbed without materially eroding profitability. Moreover, the firm’s diversified geographic footprint means that any adverse tariff adjustments in one region can be offset by stable performance elsewhere, reducing the overall risk to earnings. {bullet} The company’s investment in innovation, especially its focus on small‑price‑point molecules and the accelerated roll‑out of new products, indicates a pipeline that could capture additional share in categories where consumers are price‑sensitive. The management team’s emphasis on “highly focused innovation processes” signals a commitment to developing differentiated products that can command premium pricing within the store‑brand space, which historically yields better margins than national brands. If the company can successfully translate these pipeline initiatives into commercial success, the upside potential to organic net sales growth could be significant, especially as the broader OTC market begins to recover. {bullet} Finally, the market’s current focus on the negative aspects of the infant formula review may lead to an over‑discount of Perrigo’s OTC prospects. The narrative of a struggling infant formula unit, combined with a lowered 2025 EPS outlook, may eclipse the company’s solid share‑gain trajectory in the OTC arena. A rational reassessment of the company’s value, recognizing the momentum in OTC and the potential de‑leveraging benefits, could result in a more favorable valuation multiple that reflects the firm’s true growth trajectory.

Bear case

The strategic review of the infant formula business is a clear indicator that this segment no longer aligns with Perrigo’s core consumer health focus, and it may ultimately result in a divestiture or a complete exit from the unit. The unit’s revenue of roughly $360 million represents less than 10% of the company’s 2024 net sales, yet the associated capital expenditures and operational deficiencies—highlighted by regulatory warnings for bacterial contamination—imply a persistent risk that could erode future cash flows. The paused $240 million investment plan underscores that the company acknowledges the high cost of bringing the unit up to an acceptable standard, and any delay or failure to remediate these issues may lead to a write‑down or a forced sale at a discount, materially reducing shareholder value. {bullet} The ongoing class action litigation alleging that Perrigo misled investors about the value and condition of its infant formula business introduces a significant reputational and financial risk. If the allegations hold, the company could face substantial liability, potentially in the tens of millions, and a forced revaluation of the unit that could depress share price further. Even in the absence of a definitive settlement, the mere existence of the lawsuit can erode investor confidence and attract scrutiny from regulators, thereby affecting the company’s ability to raise capital or secure favorable financing terms. {bullet} Soft demand in the broader OTC market, driven by broader consumer health trends, has already resulted in a 4.4% decline in organic net sales for the quarter and a 1.6% drop in global OTC. Management’s statement that the consumption decline is “transitory” is contradicted by the persistent nature of the slowdown and the lack of structural evidence to support a rebound. The company’s reliance on a modest 0.6% growth in U.S. OTC volume against a backdrop of declining overall category consumption suggests that the upside is limited. In such a scenario, the company’s share‑gain achievements may be short‑lived, and the underlying revenue base may continue to shrink. {bullet} Tariff impacts of $40–$50 million, while currently being mitigated through pricing and sourcing, remain a significant pressure on gross margin. The company’s gross margin fell 110 basis points in the quarter, largely due to lower sales and unfavorable mix rather than input costs, but the introduction of tariffs adds an additional cost layer that could further compress margins if consumer demand does not recover quickly. The firm’s reliance on a single pricing strategy to offset tariff costs—namely price increases—may not be sustainable if competitors maintain lower price points, leading to potential loss of market share. {bullet} The company’s heavy focus on cost‑saving initiatives, while beneficial for short‑term margin improvement, may stifle long‑term growth if the savings are achieved at the expense of innovation and brand building. The emphasis on streamlining and reducing operational spend could limit the resources available for developing new products or expanding into new geographies. Over‑emphasis on cost control could also erode the company’s ability to compete in categories where differentiation and marketing spend are critical for capturing consumer loyalty, particularly in the highly price‑sensitive OTC space. {bullet} The planned divestiture of the dermocosmetics business, although aimed at reducing leverage, introduces uncertainty regarding the timing and potential proceeds. If the sale is delayed or priced below expectations, the anticipated reduction in net debt may not materialize as projected, keeping the company’s leverage higher than desired. Furthermore, the exit process itself could create operational disruptions, distract management, and divert attention from core OTC initiatives, thereby slowing the execution of the 3S plan and diminishing shareholder returns. {bullet} Finally, the company’s current guidance for fiscal 2025—revised organic net sales growth of minus 2% to minus 2.5% and EPS of $2.70 to $2.80—represents a contraction from previous expectations. This downward revision, driven largely by soft OTC consumption and the infant formula review, signals a cautious outlook that may dampen investor enthusiasm. Even with a reaffirmation of operating margins near 15%, the market may perceive the company as a defensive play with limited upside, especially when compared to peers that are experiencing robust growth in high‑margin categories such as personalized nutrition or advanced therapeutic OTCs.

The strategic review of the infant formula business is a clear indicator that this segment no longer aligns with Perrigo’s core consumer health focus, and it may ultimately result in a divestiture or a complete exit from the unit. The unit’s revenue of roughly $360 million represents less than 10% of the company’s 2024 net sales, yet the associated capital expenditures and operational deficiencies—highlighted by regulatory warnings for bacterial contamination—imply a persistent risk that could erode future cash flows. The paused $240 million investment plan underscores that the company acknowledges the high cost of bringing the unit up to an acceptable standard, and any delay or failure to remediate these issues may lead to a write‑down or a forced sale at a discount, materially reducing shareholder value. {bullet} The ongoing class action litigation alleging that Perrigo misled investors about the value and condition of its infant formula business introduces a significant reputational and financial risk. If the allegations hold, the company could face substantial liability, potentially in the tens of millions, and a forced revaluation of the unit that could depress share price further. Even in the absence of a definitive settlement, the mere existence of the lawsuit can erode investor confidence and attract scrutiny from regulators, thereby affecting the company’s ability to raise capital or secure favorable financing terms. {bullet} Soft demand in the broader OTC market, driven by broader consumer health trends, has already resulted in a 4.4% decline in organic net sales for the quarter and a 1.6% drop in global OTC. Management’s statement that the consumption decline is “transitory” is contradicted by the persistent nature of the slowdown and the lack of structural evidence to support a rebound. The company’s reliance on a modest 0.6% growth in U.S. OTC volume against a backdrop of declining overall category consumption suggests that the upside is limited. In such a scenario, the company’s share‑gain achievements may be short‑lived, and the underlying revenue base may continue to shrink. {bullet} Tariff impacts of $40–$50 million, while currently being mitigated through pricing and sourcing, remain a significant pressure on gross margin. The company’s gross margin fell 110 basis points in the quarter, largely due to lower sales and unfavorable mix rather than input costs, but the introduction of tariffs adds an additional cost layer that could further compress margins if consumer demand does not recover quickly. The firm’s reliance on a single pricing strategy to offset tariff costs—namely price increases—may not be sustainable if competitors maintain lower price points, leading to potential loss of market share. {bullet} The company’s heavy focus on cost‑saving initiatives, while beneficial for short‑term margin improvement, may stifle long‑term growth if the savings are achieved at the expense of innovation and brand building. The emphasis on streamlining and reducing operational spend could limit the resources available for developing new products or expanding into new geographies. Over‑emphasis on cost control could also erode the company’s ability to compete in categories where differentiation and marketing spend are critical for capturing consumer loyalty, particularly in the highly price‑sensitive OTC space. {bullet} The planned divestiture of the dermocosmetics business, although aimed at reducing leverage, introduces uncertainty regarding the timing and potential proceeds. If the sale is delayed or priced below expectations, the anticipated reduction in net debt may not materialize as projected, keeping the company’s leverage higher than desired. Furthermore, the exit process itself could create operational disruptions, distract management, and divert attention from core OTC initiatives, thereby slowing the execution of the 3S plan and diminishing shareholder returns. {bullet} Finally, the company’s current guidance for fiscal 2025—revised organic net sales growth of minus 2% to minus 2.5% and EPS of $2.70 to $2.80—represents a contraction from previous expectations. This downward revision, driven largely by soft OTC consumption and the infant formula review, signals a cautious outlook that may dampen investor enthusiasm. Even with a reaffirmation of operating margins near 15%, the market may perceive the company as a defensive play with limited upside, especially when compared to peers that are experiencing robust growth in high‑margin categories such as personalized nutrition or advanced therapeutic OTCs.

Geographical Breakdown of Revenue (2025)

Peer comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	106.63 Bn	-5.15	7.33	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	40.81 Bn	25.77	2.35	16.63 Bn
3	ZTS	Zoetis Inc.	31.90 Bn	12.51	3.35	9.05 Bn
4	UTHR	UNITED THERAPEUTICS Corp	24.99 Bn	19.62	7.88	-
5	ACB	Aurora Cannabis Inc	16.83 Bn	5.24	63.04	0.00 Bn
6	NBIX	Neurocrine Biosciences Inc	16.04 Bn	23.79	5.17	-
7	RGC	Regencell Bioscience Holdings Ltd	13.47 Bn	-	-	-
8	HCM	HUTCHMED (China) Ltd	10.84 Bn	23.83	19.76	0.09 Bn

Research Tools

PERRIGO Co plc (NYSE: PRGO)

About

Investment thesis

Bull case

Bear case

Geographical Breakdown of Revenue (2025)

Peer comparison

Research Tools

PERRIGO Co plc (NYSE: PRGO)

About

Investment thesis

Bull case

Bear case

Geographical Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password